TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03650153

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-rectal MRI targeted Biopsy
Description: Trans-rectal biopsy of the prostate: A procedure in which a sample of tissue is removed from the prostate using a thin needle that is inserted through the rectum and into the prostate.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Trans-perineal MRI targeted Biopsy
Description: Trans-perineal biopsy of the prostate: The sample is removed with a thin needle that is inserted through the skin of the perineum and into the prostate.
Study: NCT03932812

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Options Counselor Health Educator (OC-HE) Intervention
Description: The OC-HE will meet in person with the participant one time and five times via telephone to provide options counseling based on modules developed by the research team
Study: NCT01859988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT04350593

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 milligram (mg)
Description: Active Comparator: Dapagliflozin 10 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Comparator
Study: NCT03484169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The training of PNF pelvic patterns for motor learning in GI will be performed twice a week by a trained and experienced researcher for six weeks (CHRISTIANSEN et al., 2017). At each training session, there will be three repeated movements in each pelvic pattern:~Combination of isotonic (concentric, stabilizing and eccentric) of the anterior elevation pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the previous depression pattern; Combination of isotonic (concentric, stabilizing and eccentric) of the posterior elevation pattern;
Study: NCT01851993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% saline
Study: NCT01855022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI + IVR
Description: Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
Study: NCT03346239

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Gaze Contingent Music Reward Therapy
Description: Feedback according to participants' viewing patterns, in order to modify their attention.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg of Escitalopram

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Waitlist
Description: Participants will wait for 12 weeks while in touch with the clinic, then receive GC-MRT for 8 weeks.
Study: NCT01317940

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium Citrate
Description: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D and Calcium Citrate
Description: Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)~Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months
Study: NCT04670601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen Test 8.75 MG
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Reference 8.75 MG
Description: Subjects will be asked to swallow saliva before dosing. For each administration, subjects will move the lozenge around in their mouth, suck on the lozenge continually for 15 min and swallow saliva at any time during the product administration procedures, being very careful not to swallow the lozenge.
Study: NCT02976883

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [18F]HX4 diagnostic PET/CT scan
Description: Single intravenous injection of \[18F\]HX4 and PET/CT scan
Study: NCT02990000

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scientific Match
Description: We have developed an innovative, personalized Match System based on provider track records determined with a multidimensional outcomes tool - the Treatment Outcome Package (TOP). Specifically, patients are assigned to therapists with previously established strengths (i.e., being historically effective) in treating their primary problems (e.g., depression, anxiety).
Study: NCT04127370

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bariatric Surgery
Description: The Role of Bariatric Surgeries in Management of Nonalcoholic Fatty Liver Disease
Study: NCT01912976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL-PDT
Description: Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAL-PDT
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
Study: NCT03246464

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology lenses
Description: Rigid gas permeable contact lenses

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Single-vision spectacles
Description: Regular single vision spectacles
Study: NCT01183364

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STA-9090 (ganetespib) with Docetaxel
Description: One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
Study: NCT01477801

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOLECALCIFEROL
Description: Standard guideline based therapy plus cholecalciferol:~Loading dose 300.000 U then 50.000 U every month for six months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Standard guideline based therapy plus placebo
Study: NCT00869414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Evening only administration of insulin glargine
Description: Evening only administration of insulin glargine, with normal saline injection administered in the morning.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morning only administration of insulin glargine
Description: Morning only administration of insulin glargine, with normal saline injection administered at night.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: split dose insulin glargine
Description: split dose of insulin glargine, half administered in the morning, half administered in evening
Study: NCT01460303

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag
Description: OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral catheter with leg bag
Description: Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter).
Study: NCT04006145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elobixibat
Description: Elobixibat is a small molecule and a potent inhibitor of the ileal bile acid transporter (iBAT).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo identical in appearance to active drug
Study: NCT00956436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB022
Description: IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard dosing of Sorafenib
Study: NCT02887703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Augmentation
Description: Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Augmentation
Description: Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
Study: NCT03566225

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Insulin sensitizing agents

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Insulin sensitizing agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clomiphene Citrate
Description: Induction drug
Study: NCT01859988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03546400

Intervention type: DRUG
Group type: OTHER
Intervention: methylphenidate HCl ERCT
Description: methylphenidate HCl ERCT
Study: NCT01631227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eprosartan
Description: Eprosartan 450 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eprosartan Mesylate
Description: Eprosartan mesylate 600 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Eprosartan mesylate
Description: Placebo Eprosartan mesylate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Eprosartan
Description: Placebo Eprosartan
Study: NCT02822859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wright nebulizer
Description: Roxon Medi-Tech, Montreal, QC, Canada

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bennett-Twin nebulizer
Description: Puritan Bennett Corp., Carlsbad, CA, USA

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb Solo
Description: Aerogen Ltd., Galway, Ireland
Study: NCT02751541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunscreen Sport Spray (BAY987519)
Description: 50 μl/cm\*2 or 0.05 gm/cm\*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm\*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Untreated Skin
Description: This site is patched without treatment as irradiated control.
Study: NCT01177800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: 5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
Study: NCT04848701

Intervention type: OTHER
Group type: OTHER
Intervention: latent phase duration
Description: latent phase duration in post term pregnancies

Intervention type: OTHER
Group type: OTHER
Intervention: uterocervical angle (UCA)
Description: uterocervical angle is the angle between lower segment of uterus and cervix
Study: NCT03871673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sweet manioc starch
Description: 100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cornstarch
Description: 100 g of starch diluted in 200 ml of water at room temperature In the subsequent night the patient is crossed over to the other starch.
Study: NCT02321332

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral simultaneous endoscopic thoracic symapthectomy
Description: Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: unilateral sequential endoscopic thoracic symapthectomy.
Description: Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
Study: NCT01917721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 21 days besides receiveing standard care: IVIG and/or Remicade.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Standard medical care and placebo will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
Study: NCT00405366

Intervention type: DRUG
Group type: OTHER
Intervention: sorafenib tosylate
Description: Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
Study: NCT02920489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized epidural analgesia
Description: Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine epidural analgesia
Description: Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
Study: NCT02625688

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed cord clamping
Description: We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cord milking
Description: If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Early cord clamping
Description: We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
Study: NCT00580242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
Study: NCT00961480

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: place holder - do not post

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 500mg
Description: A single dose of metformin 500 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single dose of 50 mg sitagliptin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single dose of 50 mg sitagliptin tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: sitagliptin
Description: A single dose of 50 mg sitagliptin tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
Description: A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 1000 mg
Description: A single dose of metformin 1000 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: metformin 850 mg
Description: A single dose of metformin 850 mg tablet
Study: NCT04556903

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bilateral Arm Training
Description: First component of mCIMT will comprise one hour activity and a rest period of five minute given between each ten minutes of task practice. These activities will base on activities of daily living (ADL'S) and I

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: modified constrained induce movement therapy
Description: BAT involves in four sessions, each session involve repetitive practice of bilateral tasks for one hour and a rest period of 5 minutes. The tasks are:~* Block placement- 10minutes~* Peg targeting- 10 minutes~* Peg inversion-10miutes~* Transferring objects- 10minutes
Study: NCT00106587

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PTCA

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: paclitaxel coated balloon catheter (device with drug)
Study: NCT01014143

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluoride
Description: Half mouth toothbrushing twice a day for four days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine digluconate
Description: Mouth rinsing with 15 ml for 30 seconds twice a day for four days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluoride, triclosan
Description: Half mouth Brushing twice daily
Study: NCT03053518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Description: A professional, blinded, continuous glucose monitoring device will be inserted on the back of the upper arm to measure interstitial glucose every 5 min for 4 times / day.
Study: NCT03566225

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clomiphene Citrate
Description: Induction drug